New Brunswick, NJ, July 10, 2012 ― The HealthCare Institute of New Jersey (HINJ) applauds the enactment of the Food and Drug Administration Safety and Innovation Act of 2012 (S. 3187), which includes the reauthorization of the Prescription Drug User Fee Act (PDUFA) and the Medical Device User Fee Act (MDUFA). President Obama signed the legislation into law yesterday.
“The overwhelming bipartisan support of the Act garnered in both the Senate and the House clearly demonstrates PDUFA’s and MDUFA’s significant contributions to helping bring innovative, safe medicines, medical devices, technologies and therapies to American patients,” said HINJ President and Chief Executive Officer Dean J. Paranicas. “We are particularly grateful for the strong bipartisan support from members of New Jersey’s Congressional Delegation.”
“HINJ has been an avid supporter of PDUFA and MDUFA because they help the FDA keep pace with the rapidly evolving science and technology of the life sciences community that produces new treatments and cures, and contributes substantially to New Jersey’s workforce and economy,” Paranicas added.
Founded in 1997, the HealthCare Institute of New Jersey (HINJ) serves as the voice for the state’s life sciences industry. HINJ seeks to expand patient access to the most innovative biopharmaceuticals and medical devices and promote awareness of the industry’s impact on New Jersey’s quality of life and economic well-being. In 2010, HINJ member companies’ economic impact in the state exceeded $24 billion, according to HINJ’s 2011 Economic Impact Report. For more information, visit www.hinj.org.